To determine if ibrutinib inhibits downstream signalling in FLT3-ITD mutated primary AML blasts, we compared AML with FLT3-ITD to AML without FLT3-ITD in response to increasing concentrations of ibrutinib for 3 h. The gene discussed is FLT3; the disease is acute myeloid leukemia.